Innate Pharma (IPHYF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 80,476 | 96,112 | 110,957 | 49,771 | 72,727 |
| Gross Profit | 80,476 | 96,112 | 110,957 | 49,771 | 72,727 |
| Operating Expenses | 151,386 | 126,410 | 104,880 | 94,962 | 64,349 |
| Operating Income | -70,909 | -30,298 | 6,077 | -45,193 | 8,378 |
| Interest Expense | 7,725 | 5,573 | 9,955 | 11,886 | 2,166 |
| Other Income | 5,546 | 12,621 | 7,087 | 2,807 | 8,108 |
| Pre-tax Income | -73,089 | -23,250 | 3,210 | -54,273 | 14,321 |
| Income Tax | N/A | N/A | -393 | 416 | 333 |
| Net Income Continuous | -73,089 | -23,250 | 3,603 | -54,688 | 13,987 |
| Net Income | $-73,089 | $-23,250 | $3,603 | $-54,688 | $13,987 |
| EPS Basic Total Ops | -0.93 | -0.35 | 0.06 | -1.01 | 0.25 |
| EPS Basic Continuous Ops | -0.93 | -0.35 | 0.06 | -1.01 | 0.26 |
| EPS Diluted Total Ops | -0.93 | -0.34 | 0.06 | -1.01 | 0.25 |
| EPS Diluted Continuous Ops | -0.93 | -0.35 | 0.06 | -1.01 | 0.26 |
| EPS Diluted Before Non-Recurring Items | -0.30 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-6,030 | $-11,786 | $14,818 | $-40,226 | $11,989 |